Scinovex
article Open Access

A prospective study on causes and clinical manifestations of erythroderma

Abstract

Introduction: Erythroderma is a skin illness characterized by widespread inflammation, resulting in the development of erythema and scaling on more than 90% of the body's skin. Different from secondary erythroderma, which develops on top of preexisting dermatoses, primary erythroderma appears on otherwise healthy skin as a result of a systemic illness or a reaction to a medication. Materials and Methods: Participants were patients and outpatients at the dermatological clinic and ward of Department of Dermatology, Venereology & Leprosy, Shri Rama Krishna Institute of Medical Sciences & Sanaka Hospitals, Durgapur, West Bengal, India, between June 2018 to May 2019. All patients of either sex and any age who presented with a new instance of erythroderma to the dermatology clinic throughout the specified time frame were included in the analysis. Results: The study found that patients aged 50–59 had the highest prevalence of erythroderma, followed by those aged 60–69 and those aged 40–49. This is consistent with previous research that found the highest prevalence in people aged 50 to 59. Participants' mean ages were 40.25 years old. The male to female ratio has been demonstrated to be higher in previous investigations. Conclusion: The following were noted after reviewing 50 cases with erythroderma admitted to our hospital over a period of two years. The annualized frequency with which our hospital's skin clinic saw new cases of erythroderma.

Autoimmune Bullous Skin DiseasesCutaneous lymphoproliferative disorders researchToxin Mechanisms and ImmunotoxinsErythrodermaMedicineDermatologyVenereologyErythemaExfoliative dermatitisPediatrics
Citations
0
FWCI
0.00
field-weighted impact
References
20
Percentile
38%
vs. same field & year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

A prospective study on causes and clinical manifestations of erythroderma · Scinovex